Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 7/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.39 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.37 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26856967 | 0.87 | PIK3CD (0.46) | MAPK1MMP12PIK3CDPIK3CG | |
| SCHEMBL26857078 | 0.86 | ROCK1 (0.42) | MAPK1MMP12CLK1IKBKEAURKB | |
| SCHEMBL26856971 | 0.86 | MAPK1 (0.47) | MAPK1MMP12CLK1IKBKEAURKB | |
| SCHEMBL26857124 | 0.86 | MMP12 (0.39) | MMP12IKBKEAURKBTBK1PIK3CD | |
| SCHEMBL26857116 | 0.85 | ADORA2A (0.41) | MAPK1MMP12CLK1IKBKEAURKB | |
| SCHEMBL26856914 | 0.85 | MAPK1 (0.49) | MAPK1GSK3BCLK1PIK3CGMMP13 | |
| SCHEMBL26857065 | 0.85 | MAPK1 (0.46) | MAPK1MMP12MMP13 | |
| SCHEMBL26857114 | 0.84 | ADORA2A (0.44) | MAPK1MMP12IKBKEAURKBTBK1 | |
| SCHEMBL26856951 | 0.84 | ADORA2A (0.43) | MAPK1MMP12PIK3CDPIK3CGMMP13 | |
| SCHEMBL26856882 | 0.83 | MMP12 (0.53) | MAPK1GSK3BMMP12CLK1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382904-A1 | SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-30 | — | — | US | disclosed |
| US-20230382904-A1 | SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382904-A1 | SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF | SNCA, PSEN2, PARK7 | MAPK1 3172/4885TRPA1 1112/4885EPHX2 3652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.